FCCC LOGO Faculty Publications
Bellacosa A , Defeo D , Godwin AK , Bell DW , Cheng JQ , Altomare DA , Wan MH , Dubeau L , Scambia G , Masciullo V , Ferrandina G , Panici PB , Mancuso S , Neri G , Testa JR
International Journal of Cancer. 1995 Aug;64(4) :280-285
PMID: ISI:A1995RT35000011   
Back to previous list
The AKT2 gene is one of the human homologues of v-akt, the transduced oncogene of the AKT8 virus, which induces lymphomas in mice. In previous studies, AKT2, which codes for a serine-threonine protein kinase, was shown to be amplified and overexpressed in some human ovarian carcinoma cell lines and amplified in primary tumors of the ovary. To confirm and extend these findings, we conducted a large-scale, multicenter study of AKT2 alterations in ovarian and breast cancer. Southern-blot analysis demonstrated AKT2 amplification in 16 of 132 (12.1%) ovarian carcinomas and in 3 of 106 (2.8%) breast carcinomas. No AKT2 alteration was detected in 24 benign or borderline tumors. Northern-blot analysis revealed overexpression of AKT2 in 3 of 25 fresh ovarian carcinomas which were negative for AKT2 amplification. The difference in the incidence of AKT2 alterations in ovarian and breast cancer suggests a specific role for this gene in ovarian oncogenesis. No significant association was found between AKT2 amplification and amplification of the proto-oncogenes MYC and ERBB2, suggesting that amplification of AKT2 defines an independent subset of breast and ovarian cancers. Ovarian cancer patients with AKT2 alterations appear to have a poor prognosis. Amplification of AKT2 was especially frequent in undifferentiated tumors (4 of 8, P = 0.019), suggesting that AKT2 alterations may be associated with tumor aggressiveness. (C) 1995 Wiley-Liss, Inc.
ISI Document Delivery No.: RT350 Times Cited: 419 Cited Reference Count: 30 WILEY-LISS